At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed NSCLC stage III or IV
- ✓Disease stable or responding after standard chemotherapy (with or without TRT) for 3-6 months (TRACK I) or responsive after 3-6 months chemo (TRACK II at randomization)
- ✓Exactly one prior chemotherapy regimen for NSCLC (radiosensitizers allowed)
- ✓≤6 weeks from last chemotherapy or radiation dose
- ✕Untreated brain metastases
- ✕Pregnant or nursing women; females/sexual partners of childbearing potential without adequate contraception during treatment and 2 months after discontinuation
- ✕Concomitant participation in another phase III lung cancer treatment trial (TRACK I only)
- ✕Planned concurrent chemotherapy, immunotherapy, or radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 3 clinical trial evaluating carboxyamidotriazole, placebo, and 2 other interventions for Stage IIIA Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 186 participants across 1 site.
Detailed Summary
Randomized phase III trial to determine the effectiveness of carboxyamidotriazole in treating patients who have stage III or stage IV non-small cell lung cancer. Chemotherapeutic agents are modestly effective for the treatment of advanced lung cancer, with rapid tumor relapse and growth even after initial response to therapy. It is not yet known whether carboxyamidotriazole is more effective than no further treatment after standard chemotherapy for non-small cell lung cancer.
Study Details
Timeline
Interventions
Given PO
Given PO
Ancillary studies
Correlative studies